Rapid Pathogen Screening,Inc. (RPS®), an emerging manufacturer in point-of-care (POC) diagnostic testing, has secured a $6.25 million investment. Funds will be used to accelerate the growth of the company´s product development pipeline and to facilitate the continued commercial success of its existing products, the AdenoPlus® test to support the rapid diagnosis of Adenoviral conjunctivitis (pink eye) and InflammaDry™ for inflammatory dry eye disease.

RPS is strategically focused on utilizing its unique, patented technology platform to design, develop, and deliver a variety of novel and cost-effective point-of-care tests for infectious diseases and inflammatory conditions.

As a result of U.S. government contracts, this platform is also being developed to help detect the body´s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins. RPS tests allow healthcare providers to more accurately diagnose diseases, provide appropriate and timely treatment, and reduce the healthcare costs associated with spread of disease and unnecessary treatment methods.